Free Trial

Immunovant (IMVT) Stock Forecast & Price Target

$26.19
-0.61 (-2.28%)
(As of 06/18/2024 ET)

Immunovant - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$48.75
86.14% Upside
High Forecast$57.00
Average Forecast$48.75
Low Forecast$34.00
TypeCurrent Forecast
6/20/23 to 6/19/24
1 Month Ago
5/21/23 to 5/20/24
3 Months Ago
3/22/23 to 3/21/24
1 Year Ago
6/20/22 to 6/20/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.75$48.00$47.88$26.33
Forecasted Upside86.14% Upside36.33% Upside34.64% Upside54.89% Upside
Get Immunovant Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

IMVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunovant Stock vs. The Competition

TypeImmunovantMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside86.14% Upside1,068.16% Upside11.30% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
6/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $46.00+81.17%
5/30/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$51.00 ➝ $51.00+72.47%
3/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$48.00+47.69%
3/13/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+58.73%
2/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$51.00+37.36%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$55.00+45.50%
12/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$49.00 ➝ $51.00+31.61%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+25.69%
12/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$55.00 ➝ $56.00+39.83%
10/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$28.00 ➝ $57.00+64.74%
9/27/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.00 ➝ $48.00+14.75%
9/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$33.00 ➝ $50.00+25.13%
9/27/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$33.00 ➝ $48.00+20.12%
9/26/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$40.00+7.79%
7/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$28.00 ➝ $34.00+47.00%
7/10/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$14.00 ➝ $21.00+18.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:06 AM ET.

IMVT Forecast - Frequently Asked Questions

What is Immunovant's stock forecast and purchase recommendation?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunovant is $48.75, with a high forecast of $57.00 and a low forecast of $34.00. The consensus rating for Immunovant stock is Buy based on the current 17 buy ratings for IMVT. Learn more on IMVT's analyst rating history.

Do Wall Street analysts like Immunovant more than its competitors?

Analysts like Immunovant more than other "medical" companies. The consensus rating for Immunovant is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMVT compares to other companies.

Does Immunovant's stock price have much upside?

According to analysts, Immunovant's stock has a predicted upside of 40.53% based on their 12-month stock forecasts.

What analysts cover Immunovant?

Immunovant has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Oppenheimer, and Truist Financial in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:IMVT) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners